EUCTR2009-015407-47-GB进行中（未招募）1 期
A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Radiologically confirmed advanced gastric cancer
- •- One previous line of chemotherapy
- •- Progressive disease
- •- One measurable lesion
- •- Blood tests within protocol ranges
- •- (WHO) Performance Status = 1
- •- Able to sign informed consent
- •Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- No symptomatic brain metastases
- •- No coumarin type anticoagulants
- •- No liver or kidney disease
- •- No impaired heart function
- •- No pregnant or lactating women
- •Other protocol-defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
不适用
A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapyPatients with advanced gastric cancer who have progressed after one line of chemotherapyMedDRA version: 12.1Level: PTClassification code 10017758Term: Gastric cancerEUCTR2009-015407-47-NLovartis Pharma Services AG120
已完成
2 期
A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapyAdvanced gastric cancer10017991NL-OMON34887ovartis6
进行中（未招募）
不适用
A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy. - NDEUCTR2009-015407-47-ITOVARTIS FARMA120
进行中（未招募）
不适用
a clinical study comparing the efficacy and safety of AUY922, aninvestigational compound, to standard treatments in patients withadvanced gastric cancerPatients with advanced gastric cancer who have progressed after one line of chemotherapyMedDRA version: 13.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015407-47-DEovartis Pharma Services AG120
进行中（未招募）
1 期
Optimal scheme of administration of pazopanib in thyroid carcinomaIodine refractory Differentiated Thyroid CarcinomaMedDRA version: 14.1 Level: LLT Classification code 10043702 Term: Thyroid carcinoma System Organ Class: 100000004864EUCTR2012-003162-41-FRCentre Léon Bérard168